Mangoceuticals advances H1N1 study conducted by Vipragen

Mangoceuticals (MGRX) announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences, an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies. The Company is advancing to the next stage of research while also engaging Vipragen to structure a cohort for evaluating its patented respiratory illness prevention technology against the H5N1 virus. The H5N1 cohort is intended to run concurrently with the ongoing H1N1 study